Eisai Co., Ltd. (ESAIY) Stock Price & Analysis
Eisai Co., Ltd. (ESAIY) — price $8.22 (+1.11%), as of the Nov 19, 2026 trading session; market cap $9.27B.
Educational signal · not a buy or sell recommendation · How to read this
Eisai Co., Ltd. · ESAIY · Healthcare · Drug Manufacturers - Specialty & Generic
Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $8.22 | |
| Change on the day | +1.11% | |
| 52-week range | $5.69–$8.58 | |
| Market capitalisation | $9.27B | — |
| Price / earnings (trailing) | 33.77 | |
| Shares traded on the day | 2.3K | |
| Beta (volatility vs the S&P 500) | -0.07 | |
| Dividends per share (last 12 months) | $0.22 | |
| Dividend yield (last 12 months) | 2.69% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
- · Earnings results
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
For this fiscal year, as we have already reported to you, we believe that the gross profit margin is going to be controlled within the guidance.
Terushige Iike · Statement from
How to read these dates
Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations can change.
Other perspectives
Council score for Eisai Co. (ESAIY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Eisai Co. (ESAIY), and what does it report?
Short answer
Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan. Healthcare / Drug Manufacturers Specialty & Generic Headquarters: 4-6-10, Koishikawa, Tokyo, TY, 112-8088, JP. It employs 10,543 people and is led by Haruo Naito. In Q2 FY2026 it reported revenue of ¥235.63B and net income of ¥11.69B. The market values it at $9.27B.
What do the latest results show for Eisai Co. (ESAIY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of ¥235.63B.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.31B May 13, 2026
- Latest report · revenue estimate
- $195.68B May 13, 2026
- Latest report · revenue vs estimate
- Below estimate May 13, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| May 13, 2026 | $1.31B | $195.68B | −$0.0184 | Not available |
| Feb 5, 2026 | $1.43B | $212.26B | $0.0989 | Not available |
| Nov 6, 2025 | $1.34B | $197.61B | $0.0610 | $0.0691 |
| Aug 4, 2025 | $1.41B | $197.60B | $0.0900 | $0.0596 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | ¥235.63B | ¥11.69B | ¥10.37 (diluted) |
| Q1 FY2026 | ¥237.42B | ¥18.48B | ¥16.15 (diluted) |
| Q4 FY2025 | ¥209.20B | -¥3.31B | -¥2.94 (diluted) |
| Q3 FY2025 | ¥223.91B | ¥17.49B | ¥15.50 (diluted) |
What are the financial strengths and risks for Eisai Co. (ESAIY)?
Short answer · as of
The distress and quality screens read Altman Z 3.06 · Piotroski F 8. Trailing ratios: ROE 4.9% · ROA 2.9% · current ratio 2.33 · earnings yield 2.9% · free-cash-flow yield 3.4%.
What should you watch next at Eisai Co. (ESAIY)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $911.13B · EPS 53.23 · 7 analysts.
What management is planning
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $911.13B
- EPS estimate
- $53.23
Measured against a quoted price of $8.22 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ESAIY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ESAIY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Eisai Co. (ESAIY)?
What Investors Ask About Eisai Co. (ESAIY) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does Lenvima fit into Eisai's business?
Lenvima is a molecularly targeted oncology medicine used across several cancer settings, including combination treatment. It sits within an established oncology portfolio that also includes Halaven and a partnered antibody-drug conjugate program with Bristol Myers Squibb.
What is the ESAIY stock price today?
The last price recorded for Eisai Co., Ltd. (ESAIY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does ESAIY pay a dividend?
Yes. The dividend yield of Eisai Co., Ltd. (ESAIY) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 40 figures on this page — 1 from SEC filings and earnings calls, 29 from Financial Modeling Prep (FMP), 6 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com